Juni Palmgren

Juni Palmgren

Professor Emeritus/Emerita
Telephone: +46852486120
Visiting address: Nobels väg 12a, 17165 Stockholm
Postal address: C8 Medicinsk epidemiologi och biostatistik, C8 MEB III, 171 77 Stockholm
Part of:

About me

  • My statistical methods focus is on extensions of the theory of generalized linear models and failure time models to deal with multivariate responses and incomplete data. This inevitable leads to estimation procedures for complex models, including likelihood based EM strategies and Bayesian simulation based inference. The use of "causal modeling" to assess the effect of non-random non-compliance in randomized studies has been a topic of interest for a number of years. I would like in the near future to pursue the extension of this causal modeling to longitudinal observational studies.

    An earlier interest which has proven useful more recently concerns an extension of the estimation theory for generalized linear models to a situation in which each unit has a different non-linear link function. I also share the urge of many fellow biostatisticians to understand how modern statistical modeling tools are best used in the area of genetic and molecular epidemiology. Interest focuses on linkage disequilibrium mapping and association studies for case-control data and various family designs, including twins. How to deal with complex ascertainment schemes and with longitudinally measured multivariate phenotypes is included in the challenges. Most of my applied research is focused on cancer.

    Education:
    • 1973 MSc (Mathematics), University of Helsinki, Finland
    • 1987 PhD (Statistics), University of Helsinki, Finland
    • 1989 Docent (Statistics), University of Helsinki, Finland

Articles

All other publications

Grants

  • Optimization of Cervical Cancer Prevention - New challenges with HPV vaccination and primary HPV screening.
    Swedish Cancer Society
    1 January 2017
    Preventive screening against cervical cancer has greatly reduced the incidence of the disease in Sweden and many other high-income countries. The test used so far is soon replaced by one that identifies human papillomavirus (HPV), which causes cervical cancer. For almost 10 years, vaccines have been available in Sweden that protect against the most serious forms of HPV. It is mainly women aged 10-18 who have been vaccinated and these will enter the screening program in a few years. The new screening program needs to be optimized both for those who are HPV-vaccinated and for those who are not. The aim of the research project is to investigate how this process is affected by the conventional cytological screening, the new screening for finding HPV and by HPV vaccination, by means of a quantitative dynamic simulation model for the cervical cancer development process. We intend to evaluate and optimize screening for cervical cancer for women who are HPV-vaccinated and women who are not HPV-vaccinated by:    • Examine at what age the screening should start • Calculate optimal screening intervals for women of different ages We will be able to predict, plan and evaluate the costs and benefits of various strategies to prevent cervical cancer and recommend how to coordinate HPV vaccination and screening in order to prevent as much disease and death in cervical cancer as possible. The results will be in support of healthcare professionals and community planners and individual women will almost immediately benefit from improvements in the cervical cancer screening program.
  • Optimization of Cervical Cancer Prevention - New challenges with HPV vaccination and primary HPV screening.
    Swedish Cancer Society
    1 January 2016
    Preventive screening against cervical cancer has greatly reduced the incidence of the disease in Sweden and many other high-income countries. The test used so far is soon replaced by one that identifies human papillomavirus (HPV), which causes cervical cancer. For almost 10 years, vaccines have been available in Sweden that protect against the most serious forms of HPV. It is mainly women aged 10-18 who have been vaccinated and these will enter the screening program in a few years. The new screening program needs to be optimized both for those who are HPV-vaccinated and for those who are not. The aim of the research project is to investigate how this process is affected by the conventional cytological screening, the new screening for finding HPV and by HPV vaccination, by means of a quantitative dynamic simulation model for the cervical cancer development process. We intend to evaluate and optimize screening for cervical cancer for women who are HPV-vaccinated and women who are not HPV-vaccinated by:   • Examine at what age the screening should start • Calculate optimal screening intervals for women of different ages We will be able to predict, plan and evaluate the costs and benefits of various strategies to prevent cervical cancer and recommend how to coordinate HPV vaccination and screening in order to prevent as much disease and death in cervical cancer as possible. The results will be in support of healthcare professionals and community planners and individual women will almost immediately benefit from improvements in the cervical cancer screening program.
  • Repatriation Juni Palmgren
    Swedish Research Council
    1 January 2016 - 31 December 2018
  • Optimization of Cervical Cancer Prevention - New challenges with HPV vaccination and primary HPV screening.
    Swedish Cancer Society
    1 January 2015
    Preventive screening against cervical cancer has greatly reduced the incidence of the disease in Sweden and many other high-income countries. The test used so far is soon replaced by one that identifies human papillomavirus (HPV), which causes cervical cancer. For almost 10 years, vaccines have been available in Sweden that protect against the most serious forms of HPV. It is mainly women aged 10-18 who have been vaccinated and these will enter the screening program in a few years. The new screening program needs to be optimized both for those who are HPV-vaccinated and for those who are not. The aim of the research project is to investigate how this process is affected by the conventional cytological screening, the new screening for finding HPV and by HPV vaccination, by means of a quantitative dynamic simulation model for the cervical cancer development process. We intend to evaluate and optimize screening for cervical cancer for women who are HPV-vaccinated and women who are not HPV-vaccinated by:    • Examine at what age the screening should start • Calculate optimal screening intervals for women of different ages We will be able to predict, plan and evaluate the costs and benefits of various strategies to prevent cervical cancer and recommend how to coordinate HPV vaccination and screening in order to prevent as much disease and death in cervical cancer as possible. The results will be in support of healthcare professionals and community planners and individual women will almost immediately benefit from improvements in the cervical cancer screening program.
  • Swedish Research Council
    1 January 2011 - 31 January 2011
  • Basresurser till huvudsekreterare för forskningens infrastrukturer (Juni Palmgren).
    Swedish Research Council
    1 December 2010 - 30 June 2015
  • Base resources for the chief secretary of research infrastructures (June Palmgren).
    Swedish Research Council
    1 December 2010 - 30 June 2015
  • Swedish Research Council
    1 January 2010 - 31 December 2012
  • Swedish Research Council
    1 January 2009 - 31 December 2009
  • Swedish Research Council
    1 January 2009 - 31 December 2009
  • Swedish Research Council
    1 January 2009 - 31 December 2011
  • Swedish Research Council
    1 January 2008 - 31 December 2008
  • Fogarty International Center
    19 June 1989 - 31 December 1989

News from KI

Events from KI